Since AI has started acting like a 'full-fledged' worker, rules are placed outside the AI. Decoding MXC, AgentCore payments, and NVIDIA's $1 billion from primary sources

Hello, this is Uncle Llama.In the previous video, I introduced three pieces of news about generative AI.・Microsoft's ...
Cancer Network

Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study

Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved, with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus ...
Cancer Network

Preventing Moderate to Severe Dermatologic Adverse Events in First-Line EGFR-Mutant Advanced NSCLC Treated With Amivantamab Plus Lazertinib: Early Success of the COCOON Trial

Panelists discuss how amivantamab plus lazertinib therapy for EGFR-mutant non–small cell lung cancer has shown promising survival data while highlighting the importance of managing adverse events for ...